UNSPSC 51284133: Cefodizime disodium

This classification denotes a beta-lactam antibacterial with the molecular formula C20H18N6O7S4.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HC1T51593A, chemically known as (z)-7-(2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido)-3-(5-carboxymethyl-4-methylthiazol-2-ylthiomethyl)-3-cephem-4-carboxylic acid, disodium salt, but more generally known as cefodizime disodium, which bears US NIH Compound Identifier 6321412.

European Medicines Agency schedules cefodizime disodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07401MIG. Most nations, for tariff purposes, schedule cefodizime disodium under HS 29419000. SMILES: CC1C(SC(N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4CSC(N4)N)SC2)C(=O)[O-])CC(=O)[O-].[NA+].[NA+].

UNSPSC 51284133 Cefodizime disodium, a Commodity code, shows little relevant recent activity in state and local procurement. The recent opportunities tagged to this code involve pharmaceutical procurement, but neither addresses cefodizime disodium specifically—one concerns antibiotic tablets (doxycycline and ciprofloxacin) procured through a piggyback contract, and the other covers naloxone and drug deactivation systems for community health use. The misalignment between the code's nominal scope and the actual goods being solicited suggests that state and local procurement offices are either applying the code loosely to broad pharmaceutical categories or that cefodizime disodium itself is not a current procurement focus in the state and local market.

The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 (completed award, not an open solicitation), while Seminole County, Florida issued an IFB in June 2026 for annual procurement of naloxone and drug deactivation systems with a July 2026 response deadline. Geographic activity appears concentrated in Florida and Illinois based on these records, though the sparse and off-target nature of recent postings suggests limited current demand for cefodizime disodium at the state and local level. Firms pursuing this commodity should monitor pharmaceutical piggyback and cooperative purchasing vehicles in health departments, but should not expect robust near-term activity under this specific code.